Sylus

Sylus Oncology is a Houston-based biotechnology company focused on developing first-in-class small molecule inhibitors for the treatment of cancer. The company specifically targets Nicotinamide N-methyltransferase (NNMT), an enzyme that plays a critical role in the metabolic and epigenetic reprogramming of cancer cells and the tumor microenvironment. By inhibiting NNMT, Sylus aims to reverse metabolic vulnerabilities and enhance the efficacy of existing therapies. The company's lead programs are currently in the preclinical stage, targeting various solid tumors where NNMT is highly expressed. Sylus Oncology originated within the Texas Medical Center (TMC) innovation ecosystem and leverages deep expertise in cancer metabolism to address unmet needs in oncology.